Doxycycline post-exposure prophylaxis (doxy-PEP) reduces the risk of bacterial sexually transmitted infections (STIs) among men who have sex with men and transgender women. In the United States, doxy-PEP is in an early stage of integration into clinical practice, and national guidelines for its use were recently released. The goal of this manuscript is to provide practical guidance for clinicians who are considering or currently prescribing doxy-PEP. We address five clinical questions using post hoc analyses of data from the DoxyPEP randomized controlled trial and discuss the potential implications and limitations of each question with the goal of informing clinical practice and implementation of doxy-PEP programs. The questions address patient eligibility criteria for doxy-PEP, the expected benefit and associated doxy-PEP doses for the average patient, the initial number of doses prescribed, and laboratory monitoring of persons taking doxy-PEP.

中文翻译：

---

以循证方式提供多西环素暴露后预防预防细菌性传播感染


多西环素暴露后预防 （doxy-PEP） 可降低男男性行为者和跨性别女性患细菌性传播感染 （STI） 的风险。在美国，doxy-PEP 处于纳入临床实践的早期阶段，最近发布了其使用的国家指南。本手稿的目标是为正在考虑或目前正在开具 doxy-PEP 处方的临床医生提供实用指导。我们使用对 DoxyPEP 随机对照试验数据的事后分析来解决五个临床问题，并讨论每个问题的潜在影响和局限性，目的是为 doxy-PEP 计划的临床实践和实施提供信息。这些问题涉及患者接受 doxy-PEP 的资格标准、普通患者的预期益处和相关的 doxy-PEP 剂量、开出的初始剂量以及对服用 doxy-PEP 的人的实验室监测。